Immune Tolerance Inducer Using ALA and Iron Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune diseases, such as allergic and autoimmune diseases, often rely on conventional immunosuppressants with mechanisms of action that may not be entirely safe or effective, lacking a distinct approach for inducing immune tolerance.
Innovation Solution
A compound represented by the formula (I) or its salt, combined with an iron compound like sodium ferrous citrate, is used to induce regulatory dendritic cells, which can prevent and treat allergic and autoimmune diseases by promoting immune tolerance without requiring light activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressants are used to treat immune diseases, then immune response suppression is achieved, but safety and effectiveness are compromised due to lack of distinct mechanism of action
Solution Approach 1:
The invention changes the fundamental parameter of treatment mechanism by shifting from non-specific immunosuppression to specific immune tolerance induction through regulatory dendritic cell differentiation. This is achieved by using 5-aminolevulinic acid and iron compounds to modulate the differentiation pathway of dendritic cells, creating a distinct mechanism that selectively induces tolerance rather than broadly suppressing immunity, thereby improving safety while maintaining effectiveness
Solution Approach 2:
The invention introduces regulatory dendritic cells as an intermediary mechanism between the administered compounds (5-aminolevulinic acid and iron compounds) and the immune system. These regulatory dendritic cells act as mediators that actively induce immune tolerance through specific biological pathways, providing a safer and more effective approach compared to direct immunosuppression by conventional drugs
2Reliability
If ALA-PDT is used for tumor treatment, then diagnostic and therapeutic effects are achieved, but the requirement for light activation limits applicability
Solution Approach 1:
The invention extracts and separates the immune tolerance-inducing function from the light-dependent photodynamic therapy mechanism. By isolating the immunomodulatory effect of 5-aminolevulinic acid and iron compounds on dendritic cell differentiation, the invention removes the requirement for light activation, thereby maintaining treatment effectiveness while significantly improving administration convenience and broadening applicability to various immune diseases
Data Source
AI summary
An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.